With Strong Cash Flow, IQVIA Stock Poised to Rise?
IQVIA (IQV) could be a good pick for your portfolio, with its high cash yield, good fundamentals, and discounted valuation. Companies like this can use cash to fuel additional revenue growth, or simply pay their shareholders through dividends or buybacks. Either move makes them attractive to the market
What Is Happening With IQV
IQV stock is currently trading at P/S (Price-to-Sales) ratio that is at a meaningful discount to its 3-month and 2-year highs, and also below its 3-year average.
The stock may not reflect it yet, but here is what’s going well for the company. IQVIA reported a record $32.7 billion R&D backlog as of December 2025, with $8.3 billion set to convert within twelve months, indicating strong future revenue. Recent wins include a global commercial data deal with Boehringer Ingelheim and a collaboration with Duke Clinical Research Institute for obesity trials, leveraging its deep therapeutic expertise. The company’s enhanced Healthcare-grade AI strategy and proprietary Med-R1 model further solidify its market position, supporting management’s 2026 revenue guidance of $17.15 billion to $17.35 billion.
IQV Has Good Fundamentals
- Good Cash Yield: Not many stocks offer free cash flow yield of 6.8%, but IQVIA stock does
- Strong Margin: Last 12 month operating margin of 14.0%
- Growth: Last 12 revenue growth of 5.9% – low growth, but this selection is all about high yield and margin
- Valuation: IQV stock currently trading at 31% below 2Y high, 23% below 1M high, and at a PS lower than 3Y average.
Below is a quick comparison of IQV fundamentals with S&P medians.
| IQV | S&P Median | |
|---|---|---|
| Sector | Health Care | – |
| Industry | Life Sciences Tools & Services | – |
| Free Cash Flow Yield | 6.8% | 4.1% |
| Revenue Growth LTM | 5.9% | 6.6% |
| Revenue Growth 3YAVG | 4.2% | 5.4% |
| Operating Margin LTM | 14.0% | 18.8% |
| Operating Margin 3YAVG | 14.2% | 18.2% |
| PE Ratio | 22.2 | 24.9 |
*LTM: Last Twelve Months
But What Is The Risk Involved?
While IQV stock may be a compelling investment opportunity, it’s always helpful to be aware of a stock’s history of drawdown. IQV plunged nearly 19% during the 2018 correction, almost 50% in the Covid crash, and around 39% in the recent inflation shock. Even with solid fundamentals, this stock isn’t immune when things get rough. No matter how strong the story looks, big market sell-offs still hit shares hard. But the risk is not limited to major market crashes. Stocks fall even when markets are good – think events like earnings, business updates, outlook changes. Read IQV Dip Buyer Analyses to see how the stock has recovered from sharp dips in the past.
For more details and our view, see Buy or Sell IQV Stock.
Stocks Like IQV
Not ready to act on IQV? Consider these alternatives:
We chose these stocks using the following criteria:
- Greater than $2 Bil in market cap
- Dipped last month & meaningfully below 2Y high
- Current P/S < last few year average
- Strong operating margin with no instances of large margin collapse
- High free cash flow yield
A portfolio of stocks with the criteria above would have performed has follows since 12/31/2016:
- Average 6-month and 12-month forward returns of 10.4% and 20.4% respectively
- Win rate (percentage of picks returning positive) of about 74% for 12-month period
- Strategy consistent across market cycles
The Best Investors Think In Portfolios
Stocks can jump or crash but long term success comes from staying invested. The right portfolio helps you ride gains and cushion single stock drops.
Why settle for average market returns? The Trefis High Quality (HQ) Portfolio invests in a diverse group of 30 stocks that have collectively delivered stronger upside with reduced volatility compared to the broader indices. Discover the methodology behind these smoother, higher returns by checking the HQ Portfolio performance data.